Literature DB >> 3972647

[Sudden deafness--on the age dependence of therapy results with reference to naftidrofuryl (Dusodril)].

W Koehn, H J Nickol.   

Abstract

The results of treatment of 100 patients with sudden sensorineural hearing loss were analysed in three age groups (under 30, 30-60, over 60 years). The basic therapy consisted of Dextran, Diazepam and Vitamins. One half of the patients in each age group was treated with Naftidrofuryl (Dusodril) too. Sudden hearing loss was more profound in the elderly patients than in the younger ones, and the hearing gain (%) decreased with increasing age. The absolute (dB) hearing gain was more or less independent of age and Dusodril, and for all patients averaged 21 dB. Only the hearing gain (%) of the 30-60 year old patients treated with Dusodril was significantly greater than that of the control group treated without Dusodril.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3972647

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  5 in total

1.  [Value of preliminary hearing tests].

Authors:  Michael Reiss; Gilfe Reiss
Journal:  Wien Med Wochenschr       Date:  2003

2.  Therapy of hearing disorders - conservative procedures.

Authors:  Stefan Plontke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

Review 3.  Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss.

Authors:  Lekha Agarwal; David D Pothier
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

4.  [A software tool for pure-tone audiometry: Classification of audiograms for inclusion of patients in clinical trials. German version].

Authors:  T Rahne; F Buthut; S Plößl; S K Plontke
Journal:  HNO       Date:  2015-12       Impact factor: 1.284

5.  A software tool for pure‑tone audiometry. Classification of audiograms for inclusion of patients in clinical trials. English version.

Authors:  T Rahne; F Buthut; S Plößl; S K Plontke
Journal:  HNO       Date:  2016-03       Impact factor: 1.284

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.